vs
Doximity, Inc.（DOCS）与Esperion Therapeutics, Inc.（ESPR）财务数据对比。点击上方公司名可切换其他公司
Doximity, Inc.的季度营收约是Esperion Therapeutics, Inc.的1.1倍（$185.1M vs $168.4M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs 9.8%），过去两年Doximity, Inc.的营收复合增速更高（25.2% vs 10.6%）
Doximity Inc成立于2010年，是面向医疗专业人士的线上社交服务平台，为平台会员提供精选医疗资讯、远程医疗工具，以及病例协作相关功能，助力医疗从业者高效交流信息、开展诊疗相关工作。
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
DOCS vs ESPR — 直观对比
营收规模更大
DOCS
是对方的1.1倍
$168.4M
营收增速更快
ESPR
高出134.0%
9.8%
两年增速更快
DOCS
近两年复合增速
10.6%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $185.1M | $168.4M |
| 净利润 | $61.6M | — |
| 毛利率 | 89.9% | — |
| 营业利润率 | 38.9% | 50.6% |
| 净利率 | 33.3% | — |
| 营收同比 | 9.8% | 143.7% |
| 净利润同比 | -18.1% | — |
| 每股收益（稀释后） | $0.31 | $0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DOCSESPR
| Q4 25 | $185.1M | $168.4M | ||
| Q3 25 | $168.5M | $87.3M | ||
| Q2 25 | $145.9M | $82.4M | ||
| Q1 25 | $138.3M | $65.0M | ||
| Q4 24 | $168.6M | $69.1M | ||
| Q3 24 | $136.8M | $51.6M | ||
| Q2 24 | $126.7M | $73.8M | ||
| Q1 24 | $118.1M | $137.7M |
净利润DOCSESPR
| Q4 25 | $61.6M | — | ||
| Q3 25 | $62.1M | $-31.3M | ||
| Q2 25 | $53.3M | $-12.7M | ||
| Q1 25 | $62.5M | $-40.5M | ||
| Q4 24 | $75.2M | — | ||
| Q3 24 | $44.2M | $-29.5M | ||
| Q2 24 | $41.4M | $-61.9M | ||
| Q1 24 | $40.6M | $61.0M |
毛利率DOCSESPR
| Q4 25 | 89.9% | — | ||
| Q3 25 | 90.3% | — | ||
| Q2 25 | 89.2% | — | ||
| Q1 25 | 89.5% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 90.0% | — | ||
| Q2 24 | 89.3% | — | ||
| Q1 24 | 89.4% | — |
营业利润率DOCSESPR
| Q4 25 | 38.9% | 50.6% | ||
| Q3 25 | 37.8% | -11.4% | ||
| Q2 25 | 37.4% | 8.6% | ||
| Q1 25 | 35.2% | -34.0% | ||
| Q4 24 | 47.4% | -6.4% | ||
| Q3 24 | 38.8% | -31.0% | ||
| Q2 24 | 36.4% | 3.5% | ||
| Q1 24 | 35.5% | 52.5% |
净利率DOCSESPR
| Q4 25 | 33.3% | — | ||
| Q3 25 | 36.8% | -35.9% | ||
| Q2 25 | 36.5% | -15.4% | ||
| Q1 25 | 45.2% | -62.2% | ||
| Q4 24 | 44.6% | — | ||
| Q3 24 | 32.3% | -57.2% | ||
| Q2 24 | 32.7% | -83.9% | ||
| Q1 24 | 34.4% | 44.3% |
每股收益（稀释后）DOCSESPR
| Q4 25 | $0.31 | $0.32 | ||
| Q3 25 | $0.31 | $-0.16 | ||
| Q2 25 | $0.27 | $-0.06 | ||
| Q1 25 | $0.31 | $-0.21 | ||
| Q4 24 | $0.37 | $-0.14 | ||
| Q3 24 | $0.22 | $-0.15 | ||
| Q2 24 | $0.21 | $-0.33 | ||
| Q1 24 | $0.20 | $0.34 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $64.8M | $167.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $979.3M | $-302.0M |
| 总资产 | $1.2B | $465.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DOCSESPR
| Q4 25 | $64.8M | $167.9M | ||
| Q3 25 | $169.2M | $92.4M | ||
| Q2 25 | $137.3M | $86.1M | ||
| Q1 25 | $209.6M | $114.6M | ||
| Q4 24 | $165.3M | $144.8M | ||
| Q3 24 | $184.2M | $144.7M | ||
| Q2 24 | $111.4M | $189.3M | ||
| Q1 24 | $96.8M | $226.6M |
股东权益DOCSESPR
| Q4 25 | $979.3M | $-302.0M | ||
| Q3 25 | $1.1B | $-451.4M | ||
| Q2 25 | $1.0B | $-433.5M | ||
| Q1 25 | $1.1B | $-426.2M | ||
| Q4 24 | $1.0B | $-388.7M | ||
| Q3 24 | $961.2M | $-370.2M | ||
| Q2 24 | $913.6M | $-344.2M | ||
| Q1 24 | $901.4M | $-294.3M |
总资产DOCSESPR
| Q4 25 | $1.2B | $465.9M | ||
| Q3 25 | $1.3B | $364.0M | ||
| Q2 25 | $1.2B | $347.1M | ||
| Q1 25 | $1.3B | $324.0M | ||
| Q4 24 | $1.2B | $343.8M | ||
| Q3 24 | $1.1B | $314.1M | ||
| Q2 24 | $1.1B | $352.3M | ||
| Q1 24 | $1.1B | $373.1M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $60.9M | $45.2M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | 0.99× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流DOCSESPR
| Q4 25 | $60.9M | $45.2M | ||
| Q3 25 | $93.9M | $-4.3M | ||
| Q2 25 | $62.1M | $-31.4M | ||
| Q1 25 | $98.5M | $-22.6M | ||
| Q4 24 | $65.2M | $-35.0M | ||
| Q3 24 | $68.3M | $-35.3M | ||
| Q2 24 | $41.2M | $-7.2M | ||
| Q1 24 | $63.9M | $53.8M |
自由现金流DOCSESPR
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-35.5M | ||
| Q2 24 | — | $-7.3M | ||
| Q1 24 | — | $53.8M |
自由现金流率DOCSESPR
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -68.7% | ||
| Q2 24 | — | -9.9% | ||
| Q1 24 | — | 39.0% |
资本支出强度DOCSESPR
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | 0.0% | 0.0% | ||
| Q4 24 | 0.0% | 0.0% | ||
| Q3 24 | 0.0% | 0.3% | ||
| Q2 24 | 0.0% | 0.1% | ||
| Q1 24 | 0.0% | 0.1% |
现金转化率DOCSESPR
| Q4 25 | 0.99× | — | ||
| Q3 25 | 1.51× | — | ||
| Q2 25 | 1.16× | — | ||
| Q1 25 | 1.58× | — | ||
| Q4 24 | 0.87× | — | ||
| Q3 24 | 1.55× | — | ||
| Q2 24 | 1.00× | — | ||
| Q1 24 | 1.57× | 0.88× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DOCS
| Subscription | $175.4M | 95% |
| Service Other | $9.7M | 5% |
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
